At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers presented details on a new SERCA inhibitor ...
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co. Ltd. presented details on a new SERCA ...
North Korea test fired an estimated 10 ballistic missiles March 14, 2026, from its KN-25 multiple rocket launcher system. Korean Central News Agency photo North Korea recently test fired an estimated ...
An acclaimed Aussie chef has passed away following a two year fight against a rare illness.
An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...
A student-run organization at the University of Missouri, Rockin’ Against Multiple Sclerosis, is hosting philanthropic events to raise money for the Multiple Sclerosis Institute while leaving a ...
Background The purpose of this study was to clarify the usefulness of the ‘hot cross bun’ sign (HCBS) as a diagnostic imaging marker in a large cohort of patients with multiple system atrophy (MSA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results